Herpes – Cannabis Research

Herpes Research Dashboard

23

Primary Studies

10

Related Studies

33

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind Clinical Trials

1

Clinical Trials

Pre-Clinical Studies

2

Meta-analyses/Reviews

7

Animal Studies

13

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 33 studies associated with Herpes.

Here is a small sampling of Herpes studies by title:


Components of the Herpes Research Dashboard

  • Dosing information available for Herpes
  • Chemotype guidance for treating Herpes with cannabis
  • Synopsis of cannabis research for Herpes
  • Individual study details for Herpes

Ready to become a subscriber? Go to our PRICING page.

Herpes Research Dashboard

23

Primary Studies

10

Related Studies

33

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind Clinical Trials

1

Clinical Trials

Pre-Clinical Studies

2

Meta-analyses/Reviews

7

Animal Studies

13

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 33 studies associated with Herpes.

Here is a small sampling of Herpes studies by title:


Components of the Herpes Research Dashboard

  • Dosing information available for Herpes
  • Chemotype guidance for treating Herpes with cannabis
  • Synopsis of cannabis research for Herpes
  • Individual study details for Herpes

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Filter Condition

Overview - Herpes

Description of Herpes

Herpes simplex is a silent companion for many, often lurking within the body without any outward sign of its presence. Like a shadow that never quite leaves, this virus, belonging to the same family as the chickenpox-causing varicella-zoster virus, can remain dormant for years, waiting for the right moment—typically a period of weakened immunity—to reemerge. There are eight known herpes viruses, but HSV-1 (oral herpes) and HSV-2 (genital herpes) are among the most common and impactful on human health.


HSV-1, the cause of cold sores or fever blisters, typically appears around the mouth, though it can infect other areas, including the genitals, especially with changes in sexual practices. Its below-the-surface nature can create a false sense of security, as it quietly nests within the nervous system until triggered by factors like stress, fatigue, or illness. Similarly, HSV-2, more often associated with painful genital sores, thrives on the same principle: lying in wait, ready to emerge when the body’s defenses falter.


While the physical symptoms of herpes—painful blisters, sores, and skin irritation—can be managed, the emotional toll is often harder to heal. For many, the diagnosis of herpes comes with a wave of shame, anxiety, and fear of rejection. The social stigma can be more painful than the sores themselves, isolating individuals and affecting their mental health. In a culture that often links self-worth to physical perfection and sexual health, living with herpes can feel like carrying an invisible burden.


In conventional medicine, herpes is managed but not cured. Antiviral medications like Zovirax (acyclovir) have long been a staple treatment. Designed to suppress viral replication, Zovirax can help reduce the severity and duration of outbreaks and lower the chances of transmission. Yet, for many, relief comes at a cost. The side effects of acyclovir include nausea, vomiting, diarrhea, fatigue, dizziness, skin rashes, and numbness (paresthesia)—a list long enough to make some patients question whether the relief is worth the burden. And then there’s the financial impact: a month’s supply at the maximum recommended dose cost approximately $870 in 2015, a price that leaves many struggling to afford consistent treatment.


But perhaps the most profound realization for those living with herpes is that the virus doesn’t just infect the body—it weaves itself into the emotional fabric of life. For some, each outbreak is a reminder of perceived failure or vulnerability. For others, it’s a call to reflect on the beliefs they hold about themselves, their worth, and their ability to find connection despite imperfections.


This narrative of herpes—one of hidden struggles, emotional pain, and financial burden—underscores the importance of exploring complementary treatment approaches. The endocannabinoid system (ECS), along with natural terpenes like eucalyptol, pinene, and β-caryophyllene, is being investigated for its potential to manage inflammation, reduce viral activity, and promote emotional balance. As research continues, a more holistic approach may emerge, one that sees the person, not just the virus—offering relief for both the body and the soul.

Disease Classification

Condition: Herpes
Disease Family: Infectious Disease (Viral)
Organ System: Integumentary System
ICD-10 Chapter: Certain Infectious and Parasitic Diseases
ICD-10 Code: B00

Herpes Symptoms:

Itching, irritation, reddness, swelling, pain, small blister formation, cluster blisters, blister rupture, crust/scab formation

Also known as:

HSV, Herpesviral Infections, Herpes Simplex, Eczema herpeticum,

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol. 
  • THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
  • Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

CBD Interaction with Pharmaceutical Drugs

  • Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
  • Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.

If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

THC/CBD Interaction with Pharmaceutical Drugs

In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.

If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).

However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)
Top

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.